Skip to main content

Marta Olive Gadea

Institutions of which they are part

Main researcher
Stroke research
Vall Hebron Institut de Recerca

Marta Olive Gadea

Institutions of which they are part

Main researcher
Stroke research
Vall Hebron Institut de Recerca

Projects

Aplicación de estrategias para agilizar el tratamiento de pacientes con ictus agudo

IP: Marc Ribó Jacobi
Collaborators: Marta Olive Gadea, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 65000
Reference: CM23/00280
Duration: 31/03/2024 - 30/03/2026

HARMONICS. Harmonization and Implementation of High Value Stroke Care

IP: Carlos Molina Cateriano
Collaborators: Maria Baladas Orti, Ester Sanchez Gavilan, Cristina Guirao Martinez, Estefania Montiel, Marina Jimenez Iglesias, Lidia Garcia Guillamón, Federica Rizzo, Marta Aurora Rubiera Del Fueyo, David Rodriguez Luna, Manuel Requena Ruiz, Marta Olive Gadea, Alvaro Garcia Tornel Garcia Camba, Marc Rodrigo Gisbert
Funding agency: EUROPEAN COMMISSION
Funding: 468090
Reference: HARMONICS_EIT-HEALTH-BP2022
Duration: 01/01/2022 - 31/12/2024

Aplicación de estrategias basadas en ciencia de datos y machine learning en la investigación en ictus

IP: Carlos Molina Cateriano
Collaborators: Marta Olive Gadea
Funding agency: Fundació Institut de Recerca HUVH
Funding: 117000
Reference: HUVH/BPFSE_RENOV/2021/OLIVÉ
Duration: 01/06/2021 - 30/05/2023

ARTERIAL: un marco de IA para la planificación de operación a través de la caracterización automática de la tortuosidad vascular

IP: Marta Olive Gadea
Collaborators: Marc Ribó Jacobi
Funding agency: Instituto de Salud Carlos III
Funding: 107690
Reference: PI21/01967
Duration: 01/01/2022 - 31/12/2024

Related news

UMBRELLA, a consortium of over 20 public and private partners, kicks off this week with the aim of revolutionising the entire stroke care pathway in Europe by adopting a holistic approach that covers stroke diagnosis, prevention and care.

The Consortium will create a platform to facilitate a personalised management for stroke patients, enabling a more efficient personalized monitoring and patient follow up.

Funding is key to bringing the neuroprotective drug ApTOLL to market and providing a new therapeutic option for the patients.

Related professionals

Marta Sanchiz Cruz

Marta Sanchiz Cruz

Research technician
Infectious Diseases
Read more
M. Mercè Fabregat  Bosch

M. Mercè Fabregat Bosch

Reconstructive Surgery of the Locomotor System
Read more
Jordi Giralt López de Sagred

Jordi Giralt López de Sagred

Read more
Angel Manuel Lorente Cobo

Angel Manuel Lorente Cobo

Auxiliar Tècnic/a Recerca
Experimental Surgery Unit (ESU)
Preclinical Core Facilities
External Strategy Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.